A Phase I Study of Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer.
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2016
At a glance
- Drugs Dovitinib (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 20 Apr 2016 Status changed from suspended to discontinued.
- 04 Feb 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 27 Jul 2012 Actual initiation date (Jul 2012) added as reported by ClinicalTrials.gov.